Ionis Climbs As FDA Clears New Therapy To Lower Triglycerides, Pancreatitis Risk - Ionis Pharmaceuticals

Ionis wins FDA label expansion for potential blockbuster triglycerides indication

Ionis wins FDA approval to expand Tryngolza into severe hypertriglyceridemia, a far larger market than its rare FCS launch, with peak US sales seen topping $3B.